-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を13ドル引き上げ、141ドルとします。これは、2026年のFFO予想の18.6倍に相当し、過去3年間の平均予想倍率14.7倍を上回る水準です。これは、リース料スプレッドが引き続き好調で、2026年の見通しも良好であるためです。2026年のFFO予想は7.58ドルで据え置き、2027年の予想は0.13ドル引き上げ、7.82ドルとします。FRTは、第1四半期にリース件数が過去最高を記録したことに加え、リース料の力強い成長が継続しています。当社の見解では、ポートフォリオ（最近取得した物件を除く）は稼働率がほぼピークに達しており、経営陣は今後もテナントを厳選し、2027年まで10%以上のキャッシュフローを生み出すことができると考えています。FRTの現在のパイプライン（1億7500万ドル～2億2500万ドル）の開発コストは増加する可能性がありますが、当社の下振れシナリオでも利回りは8.5%を超えると見ています。2026年度については、FRTが引き続き積極的に新たな買収対象を探し続けるため、既存物件の純営業利益（NOI）は4.5%～5.5%増加すると予測しています。
Related Articles
Research
Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of Aptargroup, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target at $149, 26.8x our 2026 EPS estimate, a premium to its three-year average forward P/E of 26.5x. We trim our 2026 EPS view by $0.12 to $5.56 and decrease our 2027 EPS by $0.15 to $6.40. The injectables division continues to validate our thesis, with 20% Y/Y growth in Q1 as management actively works to increase capacity so the division can expand further. We note that emergency medicine faces a $65M headwind in 1H 2026 as it destocks from prior inventory, which led to flat Q1 core sales and weaker gross margins. Management is confident its pharma growth will expand beyond GLP-1 to both systemic nasal drug delivery and pulmonary biologics. Margin weakness and an unfavorable mix in the Beauty segment are temporary, with normal margins returning in 2H 2026 in our view. We continue to believe ATR is poised to capture significant growth in the biologics markets. ATR could face higher raw material costs as supply chains become stretched due to uncertainty in the Middle East.
$ATR
Asia
Lottery Secures Agreement for 40-Year License Extension
Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.
$ASX:TLC
Asia
Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%
Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.
$ASX:GTK$NZE:GTK